The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Archives of Internal Medicine

• Publication date

  2002-11-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/ARCHINTE.162.21.2428PMID 12437401
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacotherapy for obesity.

  2002cited by this paper
• Weight change and blood coagulability and fibrinolysis in healthy obese women

  2001cited by this paper
• Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X.

  2001cited by this paper
• Body Fat Distribution and Total Body Fat as Risk Factors for Microalbuminuria in the Obese

  2001cited by this paper
• Microalbuminuria, central adiposity and hypertension in the non-diabetic urban population of the MONICA Augsburg survey 1994/95

  2001cited by this paper
• The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study

  2001cited by this paper
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

  2000cited by this paper
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome.

  2000cited by this paper
• One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor

  2000cited by this paper
• Intentional weight loss and mortality among overweight individuals with diabetes.

  2000cited by this paper
• Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults.

  2000cited by this paper
• Adipose tissue as an endocrine organ.

  2000cited by this paper
• The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study

  2000cited by this paper
• Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.

  2000cited by this paper
• The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus.

  2000cited by this paper
• Stemming the tide: reducing cardiovascular disease and renal failure in Australian Aborigines.

  1999cited by this paper
• Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension

  1999cited by this paper
• Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.

  1999cited by this paper
• Prospective study of intentional weight loss and mortality in overweight white men aged 40-64 years.

  1999cited by this paper
• Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

  1999cited by this paper
• Prediction of hypertension, diabetes, dyslipidaemia or albuminuria using simple anthropometric indexes in Hong Kong Chinese

  1999cited by this paper
• The role of TNFalpha and TNF receptors in obesity and insulin resistance.

  1999cited by this paper
• The role of TNFα and TNF receptors in obesity and insulin resistance

  1999cited by this paper
• Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators.

  1999cited by this paper
• Pharmacotherapy for obesity.

  1999cited by this paper
• Tests of scaling assumptions and construct validity of the Chinese (HK) version of the SF-36 Health Survey.

  1998cited by this paper
• TNF-alpha and insulin resistance: summary and future prospects.

  1998cited by this paper
• Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study

  1998cited by this paper
• Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

  1998cited by this paper
• Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.

  1998cited by this paper
• TNF-α and insulin resistance: Summary and future prospects

  1998cited by this paper
• Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients

  1998cited by this paper
• Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

  1997cited by this paper
• A one-year trial to assess the value of orlistat in the management of obesity.

  1997cited by this paper
• Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM

  1997cited by this paper
• Visceral Fat and Cardiovascular Risk Factors in Chinese NIDDM Patients

  1997cited by this paper
• Insulin resistance and obesity

  1996cited by this paper
• The Metabolic Syndrome in Hong Kong Chinese. The interrelationships among its components analyzed by structural equation modeling

  1996cited by this paper
• Mechanism of free fatty acid-induced insulin resistance in humans.

  1996cited by this paper
• The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle.

  1996cited by this paper
• Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years.

  1995cited by this paper
• Assessment of insulin action and glucose effectiveness in diabetic and nondiabetic humans.

  1994cited by this paper
• Retrospective population‐based analysis of the dose‐response (fecal fat excretion) relationship of orlistat in normal and obese volunteers

  1994cited by this paper
• Cardiovascular risk factors in non-insulin-dependent diabetic subjects with microalbuminuria.

  1993cited by this paper
• Beneficial health effects of modest weight loss

  1992cited by this paper
• Beneficial health effects of modest weight loss.

  1992cited by this paper
• Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease

  1991cited by this paper
• Obesity, Weight Loss and Prognosis in Type 2 Diabetes

  1990cited by this paper
• Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease.

  1990cited by this paper
• Type II Diabetic Subjects Lose Less Weight Than Their Overweight Nondiabetic Spouses

  1987cited by this paper
• Long-term effects of modest weight loss in type II diabetic patients.

  1987cited by this paper
• Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man

  1985cited by this paper
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper

• Phenolic acids from Anisopus mannii modulates phosphofructokinase 1 to improve glycemic control in patients with type 2 diabetes: a double-blind, randomized, clinical trial.

  2025cites this paper
• Synthetic pancreatic lipase inhibitors in obesity treatment: current updates on in silico design, synthesis, bioactivity, and SAR.

  2025cites this paper
• Why does type 2 diabetes mellitus impair weight reduction in patients with obesity? A review

  2023cites this paper
• Obesity and Chronic Kidney Disease.

  2022cites this paper
• Associations between the incidence and mortality rates of type 2 diabetes mellitus and long-term exposure to ambient air pollution: A 12-year cohort study in northern China.

  2020cites this paper
• Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial

  2019cites this paper
• The Role of Anti-Obesity Medication in Prevention of Diabetes and Its Complications

  2019influential citation
• Obesity in Kidney Disease

  2019cites this paper
• [Not Available].

  2016cites this paper
• AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.

  2016cites this paper
• Efecto del tratamiento de dos días con orlistat sobre los niveles de leptina plasmática en pacientes obesas sin pérdida de peso

  2016cites this paper
• Effect of two days treatment with orlistat on plasma leptin in obese patients without weight loss

  2016cites this paper
• Weight Loss Interventions and Progression of Diabetic Kidney Disease

  2015cites this paper
• Obesity in CKD--what should nephrologists know?

  2013cites this paper
• Effects of weight loss on renal function in obese CKD patients: a systematic review.

  2013influential citation
• A Model of Long-term Metabolic Progression of Type 2 Diabetes Mellitus for Evaluating Treatment Strategies

  2013cites this paper
• Orlistat

  2012cites this paper
• Management of Obesity-Induced Kidney Disease: A Critical Review of the Literature

  2012cites this paper
• Metabolic Syndrome: Prevalence and Risk Factors in Southern China

  2010cites this paper
• Recent Advances in the Use of Orlistat in the Treatment of Abdominal Obesity and Associated Cardiometabolic Risk Factors

  2010cites this paper
• The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents

  2010cites this paper
• A High-Protein Diet With Resistance Exercise Training Improves Weight Loss and Body Composition in Overweight and Obese Patients With Type 2 Diabetes

  2010cites this paper
• The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents

  2010cites this paper
• Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts.

  2010influential citation
• Obesity and arterial compliance alterations.

  2010cites this paper
• Obesity and changes in urine albumin/creatinine ratio in patients with type 2 diabetes: the DEMAND study.

  2010cites this paper
• Effect of Orlistat-Assisted Weight Loss on Endothelium-Dependent Vasodilation in Obese Chinese Subjects with Hypertension

  2010cites this paper
• Weight loss and proteinuria : systematic review of clinical trials and comparative cohorts

  2010influential citation
• Effects of orlistat, alone or combined with hypolipidemic drugs, on cardiovascular risk factors

  2009cites this paper
• Current pharmacotherapeutic concepts for the treatment of obesity in adults

  2009cites this paper
• Metabolism in Hepatocytes and Adipocytes under inhibition of carbonic anhydrases studied with multinuclear NMR-spectroscopy

  2009cites this paper
• The effects of diet and orlistat on body weight and lipid profiles in high risk Chinese patients with coronary artery disease, obesity and hypercholesterolemia

  2009cites this paper
• Association between Changes in Obesity Parameters and Incidence of Chronic Kidney Disease in Japanese Individuals

  2009cites this paper
• Lipid-lowering drugs acting at the level of the gastrointestinal tract.

  2009cites this paper
• Management of the Obese Patient

  2008cites this paper
• Orlistat-Associated Adverse Effects and Drug Interactions

  2008cites this paper
• Orlistat in the prevention of diabetes in the obese patient

  2008cites this paper
• Burden of Obesity – lessons learnt from Hong Kong Chinese

  2008cites this paper
• Trends in Overweight and Obesity in Chinese Adults: Between 1991 and 1999–2000

  2008cites this paper
• Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.

  2007influential citation
• Orlistat Reverse Fatty Infiltration and Improves Hepatic Fibrosis in Obese Patients with Nonalcoholic Steatohepatitis (NASH)

  2007cites this paper
• Low levels of awareness of suboptimal health conditions in a high-risk working population: The “better health for better Hong Kong” health promotion campaign

  2007cites this paper
• Effectiveness of a lifestyle modification programme in weight maintenance in obese subjects after cessation of treatment with Orlistat.

  2007cites this paper
• [Impact of weight loss on adipocytokines, C-reactive protein and insulin sensitivity in hypertensive women with central obesity].

  2007cites this paper
• Mortality in men admitted to hospital with acute urinary retention

  2007cites this paper
• Impact of weight change on albuminuria in the general population.

  2007cites this paper
• Excess weight as a risk factor for kidney failure

  2007cites this paper
• AN INTERNATIONAL PERSPECTIVE ON OBESITY, HEALTH AND PHYSICAL ACTIVITY: CURRENT TRENDS AND CHALLENGES IN CHINA AND ASIA

  2007cites this paper
• Impacto da perda de peso nas adipocitocinas, na proteína C-reativa e na sensibilidade à insulina em mulheres hipertensas com obesidade central

  2007cites this paper
• The metabolic syndrome and vascular disease in Asia.

  2007cites this paper
• Nutritional strategies for patients with obesity and the metabolic syndrome

  2006cites this paper
• Licorice Flavonoid Oil Effects Body Weight Loss by Reduction of Body Fat Mass in Overweight Subjects

  2006cites this paper
• Effekte von Orlistat auf die Insulinsensitivität und den intramyozellulären Lipidgehalt bei insulinresistenten nicht-diabetischen Personen, unabhängig von der Gewichtsabnahme

  2006cites this paper
• Effects of eight weeks of exercise training and orlistat therapy on body composition and maximal exercise capacity in obese females.

  2006cites this paper
• Effect of long‐term orlistat treatment on serum levels of advanced glycation end‐products in women with polycystic ovary syndrome

  2006cites this paper
• Guías ALAD 2006 de diagnóstico control y tratamiento de la Diabetes Mellitus Tipo 2.

  2006cites this paper
• The metabolic syndrome in China.

  2006cites this paper
• Risk Assessment and Treatment Standards of Obesity and Overweight in Relation to Cardiovascular Disease

  2006cites this paper
• Role of diet in the treatment of polycystic ovary syndrome.

  2006cites this paper
• Obesidad: aspectos patogénicos, alteraciones cardiovasculares asociadas y estrategias terapéuticas Obesity: pathogenic issues, associated cardiovascular illness, and therapeutic approach

  2005cites this paper
• Effects of agar (kanten) diet on obese patients with impaired glucose tolerance and type 2 diabetes

  2005cites this paper
• Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.

  2005cites this paper
• A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin

  2005cites this paper
• The cardiovascular continuum in Asia--a new paradigm for the metabolic syndrome.

  2005cites this paper
• Genomewide linkage analysis of weight change in the Framingham Heart Study.

  2005cites this paper
• The effects of orlistat on metabolic parameters and other cardiovascular risk factors.

  2005cites this paper
• Metabolic syndrome and type 2 diabetes: the Hong Kong perspective.

  2005cites this paper
• Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose.

  2005cites this paper
• Practical Tips for Prescribing Anti-obesity Drugs

  2004cites this paper
• Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women

  2004cites this paper
• Nutrition and metabolism

  2004cites this paper
• Pharmacological and surgical treatment of obesity.

  2004cites this paper
• Pérdida ponderal, orlistat y lipemia posprandial

  2003cites this paper
• Lessons learned from young-onset diabetes in China

  2003cites this paper
• Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial

  2003cites this paper
• Call for Action Statement from the Joint Meeting of the 3 rd World Congress on Prevention of Diabetes and Its Complications and 4 th Hong Kong Diabetes and Cardiovascular Risk Factor – East Meets West

  2003cites this paper